Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food on the Pharmacokinetics of BI 425809 in Healthy Subjects
NCT05347004Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of iclepertin in schizophrenia (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point and Maximum Measured Concentration of BI 425809 in Plasma. Started Oct 2022; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05347004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347004.